Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.
Article
Oncology
Rita C. Acurcio, Sabina Pozzi, Barbara Carreira, Marta Pojo, Nuria Gomez-Cebrian, Sandra Casimiro, Adelaide Fernandes, Andreia Barateiro, Vitor Farricha, Joaquim Brito, Ana Paula Leandro, Jorge A. R. Salvador, Luis Graca, Leonor Puchades-Carrasco, Luis Costa, Ronit Satchi-Fainaro, Rita C. Guedes, Helena F. Florindo
Summary: This study identifies a new class of small molecule candidates that can regulate the PD-L1/PD-1 signaling pathway, promoting the infiltration of effector CD8 T cells in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Pushpamali De Silva, Marco Aiello, Chunyan Gu-Trantien, Edoardo Migliori, Karen Willard-Gallo, Cinzia Solinas
Summary: Immunotherapy approaches targeting immune checkpoint molecules like CTLA-4 have revolutionized treatment of solid tumors and hematological malignancies by enhancing antitumor immune responses. However, the use of anti-CTLA-4 Abs may lead to autoimmune-like adverse events, though this higher incidence is associated with improved clinical benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Ze Xiang, Jiayuan Li, Zhengyu Zhang, Chao Cen, Wei Chen, Bin Jiang, Yiling Meng, Ying Wang, Bjoern Berglund, Guanghua Zhai, Jian Wu
Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pathology
Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee
Summary: This review focuses on the impact of PD-L1 on combo nivolumab-ipilimumab therapy in advanced solid cancer patients, indicating that patient responses can be affected by different levels of PD-L1 expression. Variations in responses are observed among different cancer types or doses of immunotherapy drugs. Therefore, relying solely on PD-L1 as a biomarker may not be reliable for predicting the clinical efficacy of combo nivolumab-ipilimumab. Other biomarkers or a combination of PD-L1 with other factors should be considered for predicting patient responses.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Review
Oncology
Liming Liao, Huilin Xu, Yuhan Zhao, Xiaofeng Zheng
Summary: Immunotherapies based on immune checkpoint blockade have improved cancer therapy outcomes in the past decade. However, some patients show poor responsiveness to this therapy, and the underlying mechanism is not well understood. Recent studies have shown that targeting tumor metabolism in combination with immune checkpoint inhibitors provides new approaches to cancer therapy.
FRONTIERS OF MEDICINE
(2023)
Review
Medicine, Research & Experimental
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Summary: Immunotherapy and oncolytic virotherapy have revolutionized cancer treatment. The combination of monoclonal antibodies targeting PD-1/PD-L1 with oncolytic Ads has shown promising potential in improving clinical responses to immune checkpoint inhibitors.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Li Xu, Xin Yan, Weiyue Ding
Summary: This meta-analysis study suggests that immune checkpoint inhibitors (ICIs) are associated with significant improvements in progression-free survival (PFS) and overall survival (OS) compared to non-ICI therapies.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan
Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Anastasia Gangaev, Elisa A. Rozeman, Maartje W. Rohaan, Olga I. Isaeva, Daisy Philips, Sanne Patiwael, Joost H. van den Berg, Antoni Ribas, Dirk Schadendorf, Bastian Schilling, Ton N. Schumacher, Christian U. Blank, John B. A. G. Haanen, Pia Kvistborg
Summary: PD-1 blockade may primarily affect T cell composition in peripheral blood, while CTLA-4 blockade may result in the expansion of melanoma-reactive CD8 T cell response in peripheral blood.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Medicine, Research & Experimental
Parisa Shiri Aghbash, Narges Eslami, Ali Shamekh, Taher Entezari-Maleki, Hossein Bannazadeh Baghi
Summary: The COVID-19 pandemic, caused by the outbreak of SARS-CoV-2 in Wuhan in December 2019, highlights the significance of respiratory disorders, lymphopenia, cytokine cascades, and immune responses in disease severity. Investigation of inhibitory immune checkpoints could impact treatment strategies, with T-cells playing a key role in clearing viral infections and reducing symptoms. Lymphocyte depletion and enhanced expression of inhibitory immune checkpoints in individuals with COVID-19 contribute to T-cell dysfunction and exhaustion, particularly in severe cases.
Article
Oncology
Byoung Chul Cho, Kiyotaka Yoh, Ruth Perets, Adnan Nagrial, David R. Spigel, Martin Gutierrez, Dong-Wan Kim, Dusan Kotasek, Drew Rasco, Jiaxin Niu, Miyako Satouchi, Myung-Ju Ahn, Dae Ho Lee, Corinne Maurice-Dror, Shabana Siddiqi, Yixin Ren, Rachel A. Altura, Jair Bar
Summary: The study demonstrated promising antitumor activity of quavonlimab + pembrolizumab in patients with extensive-stage SCLC, with responses observed in both PD-L1-positive and PD-L1-negative tumors, and manageable tolerability.
Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Meeting Abstract
Oncology
Arjun Gupta, Siddharth Singh, Preet Paul Singh
JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Surgery
Natalia S. Tucker, Amy E. Cyr, Foluso O. Ademuyiwa, Adel Tabchy, Krystl George, Piyush K. Sharma, Linda X. Jin, Souzan Sanati, Rebecca Aft, Feng Gao, Julie A. Margenthaler, William E. Gillanders
Review
Gastroenterology & Hepatology
Kaustav Majumder, Arjun Gupta, Nivedita Arora, Preet Paul Singh, Siddharth Singh
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2016)
Article
Biochemistry & Molecular Biology
N. V. Sankpal, T. P. Fleming, P. K. Sharma, H. J. Wiedner, W. E. Gillanders
Article
Immunology
Xiuli Zhang, Piyush K. Sharma, S. Peter Goedegebuure, William E. Gillanders
Article
Oncology
Sandip P. Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine McLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles Blanke, Razelle Kurzrock
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Robert J. Torphy, Camille Stewart, Piyush Sharma, Alison L. Halpern, Kristen Oase, Whitney Herter, Christan Bartsch, Chloe Friedman, Marco Del Chiaro, Richard D. Schulick, Ana Gleisner, Martin D. McCarter, Steven A. Ahrendt
ANNALS OF SURGICAL ONCOLOGY
(2020)
Article
Immunology
Robert A. Watson, Orion Tong, Rosalin Cooper, Chelsea A. Taylor, Piyush K. Sharma, Alba Verge de Los Aires, Elise A. Mahe, Helene Ruffieux, Isar Nassiri, Mark R. Middleton, Benjamin P. Fairfax
Summary: This study used single-cell sequencing technology to track the gene expression changes of CD8(+) T cells in response to immune checkpoint blockade (ICB), finding different reactivity across CD8(+) T cell subsets and showing that cytotoxic effector subsets exhibited the most gene expression changes post-ICB. Larger CD8(+) T cell clones had more differentially regulated genes after ICB, with a correlation between clone size and transcriptional changes enriched in T cell receptor signaling pathways. Cytotoxic effector CD8(+) clones were more likely to persist post-ICB and corresponded with public tumor-infiltrating lymphocyte clonotypes. Individuals with low cytotoxicity and fewer expanded CD8(+) T cell clones before treatment tended to have worse outcomes after ICB.
SCIENCE IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chelsea A. Taylor, Robert A. Watson, Orion Tong, Weiyu Ye, Isar Nassiri, James J. Gilchrist, Alba Verge de los Aires, Piyush Kumar Sharma, Surya Koturan, Rosalin A. Cooper, Victoria K. Woodcock, Elsita Jungkurth, Brian Shine, Nicholas Coupe, Miranda J. Payne, David N. Church, Vivek Naranbhai, Stefan Groha, Paul Emery, Kulveer Mankia, Matthew L. Freedman, Toni K. Choueiri, Mark R. Middleton, Alexander Gusev, Benjamin P. Fairfax
Summary: Treatment with immune checkpoint blockade is associated with increased risk of immune-related adverse events, and this risk is influenced by the gene rs16906115 and IL7 expression. Patients carrying the risk allele show increased pre-treatment B cell IL7 expression, which is associated with adverse events risk and immune response.
Review
Surgery
Adam R. Dyas, David Thor Johnson, Erin Rubin, Richard D. Schulick, Piyush Kumar Sharma
JOURNAL OF SURGICAL CASE REPORTS
(2020)
Review
Oncology
Piyush K. Sharma, Sanjana Mehrotra, Ana L. Gleisner, Richard D. Schulick, Martin D. McCarter
JOURNAL OF PANCREATIC CANCER
(2018)
Article
Biotechnology & Applied Microbiology
Piyush K. Sharma, Igor P. Dmitriev, Elena A. Kashentseva, Geert Raes, Lijin Li, Samuel W. Kim, Zhi-Hong Lu, Jeffrey M. Arbeit, Timothy P. Fleming, Sergey A. Kaliberov, S. Peter Goedegebuure, David T. Curiel, William E. Gillanders
CANCER GENE THERAPY
(2018)
Meeting Abstract
Oncology
Piyush Sharma, Amy Cyr
ANNALS OF SURGICAL ONCOLOGY
(2016)
Article
Medicine, General & Internal
Prashant Singh, Piyush Kumar Sharma, Abhishek Agnihotri, Viveka P. Jyotsna, Prasenjit Das, Siddhartha Datta Gupta, Govind K. Makharia, Rajesh Khadgawat
NATIONAL MEDICAL JOURNAL OF INDIA
(2015)
